Olaparib in Patients With HRD Malignant Mesothelioma
Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma
Sponsor: AstraZeneca
Listed as NCT04515836, this PHASE2 trial focuses on Homologous Recombination Deficiency and Mesothelioma and remains actively recruiting participants. Sponsored by AstraZeneca, it has been updated 12 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Jun 2025 — Present [monthly]
Recruiting PHASE2
-
Nov 2024 — Jun 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
May 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Jun 2021 — May 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .